Piper Jaffray lowers their price target on Brightpoint (NASDAQ: CELL) from $13 to $12, but maintains their Buy rating. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE